Successfully treated thrombocytopenia following allogeneic transplant with daratumumab: a case report and literature review
2020
A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations. A short course of daratumumab is a novel treatment of refractory thrombocytopenia after failure of standard treatment options.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
12
References
12
Citations
NaN
KQI